1,500 Shares in Illumina, Inc. (ILMN) Purchased by grace capital

grace capital acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent filing with the SEC. The fund acquired 1,500 shares of the life sciences company’s stock, valued at approximately $420,000.

Several other large investors also recently added to or reduced their stakes in the stock. Banco de Sabadell S.A raised its stake in shares of Illumina by 317.8% during the 2nd quarter. Banco de Sabadell S.A now owns 6,684 shares of the life sciences company’s stock valued at $1,854,000 after purchasing an additional 5,084 shares during the period. Tower Research Capital LLC TRC bought a new stake in shares of Illumina during the 2nd quarter valued at $1,220,000. Marshall Wace LLP raised its stake in shares of Illumina by 166.4% during the 2nd quarter. Marshall Wace LLP now owns 17,738 shares of the life sciences company’s stock valued at $4,954,000 after purchasing an additional 11,080 shares during the period. Zacks Investment Management raised its stake in shares of Illumina by 30.9% during the 2nd quarter. Zacks Investment Management now owns 27,649 shares of the life sciences company’s stock valued at $7,722,000 after purchasing an additional 6,527 shares during the period. Finally, Arrowgrass Capital Partners US LP raised its stake in shares of Illumina by 71.8% during the 2nd quarter. Arrowgrass Capital Partners US LP now owns 104,312 shares of the life sciences company’s stock valued at $29,133,000 after purchasing an additional 43,599 shares during the period. Institutional investors own 89.83% of the company’s stock.

In other news, SVP Mostafa Ronaghi sold 7,500 shares of the company’s stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $288.89, for a total value of $2,166,675.00. Following the completion of the transaction, the senior vice president now directly owns 78,496 shares in the company, valued at approximately $22,676,709.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert S. Epstein sold 500 shares of the company’s stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $288.45, for a total value of $144,225.00. Following the completion of the transaction, the director now owns 6,639 shares of the company’s stock, valued at $1,915,019.55. The disclosure for this sale can be found here. Insiders sold a total of 42,537 shares of company stock valued at $13,779,035 over the last quarter. Company insiders own 0.54% of the company’s stock.

Illumina stock opened at $355.91 on Friday. Illumina, Inc. has a 52 week low of $196.00 and a 52 week high of $357.93. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.44. The stock has a market cap of $51.42 billion, a P/E ratio of 88.98, a price-to-earnings-growth ratio of 2.90 and a beta of 0.97.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The business had revenue of $830.00 million during the quarter, compared to analysts’ expectations of $786.88 million. During the same period in the previous year, the business earned $0.82 earnings per share. The firm’s revenue was up 25.4% on a year-over-year basis. equities research analysts predict that Illumina, Inc. will post 5.46 earnings per share for the current fiscal year.

ILMN has been the topic of a number of analyst reports. Canaccord Genuity boosted their price objective on Illumina from $270.00 to $290.00 and gave the company a “top pick” rating in a research note on Tuesday, May 29th. Morgan Stanley boosted their price objective on Illumina from $180.00 to $195.00 and gave the company an “underweight” rating in a research note on Thursday, May 31st. Citigroup boosted their price objective on Illumina from $275.00 to $330.00 and gave the company a “buy” rating in a research note on Monday, June 25th. Cowen boosted their price objective on Illumina from $275.00 to $315.00 and gave the company an “outperform” rating in a research note on Tuesday, July 10th. Finally, Piper Jaffray Companies boosted their target price on Illumina from $272.00 to $329.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 17th. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. Illumina has a consensus rating of “Buy” and a consensus target price of $308.25.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: Return on Investment (ROI)

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply